Zacks Downgrades Harvard Bioscience to Neutral (HBIO)
Harvard Bioscience (NASDAQ:HBIO) was downgraded by Zacks to a “neutral” rating in a research report issued to clients and investors on Tuesday. They currently have a $4.80 price target on the stock. Zacks‘s price target indicates a potential upside of 1.91% from the stock’s previous close.
Harvard Bioscience (NASDAQ:HBIO) traded up 3.52% during mid-day trading on Tuesday, hitting $4.71. 502,085 shares of the company’s stock traded hands. Harvard Bioscience has a 1-year low of $3.5557 and a 1-year high of $5.15. The stock has a 50-day moving average of $4.06 and a 200-day moving average of $4.41. The company’s market cap is $150.5 million.
Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.03 by $0.02. The company had revenue of $25.90 million for the quarter, compared to the consensus estimate of $26.10 million. Analysts expect that Harvard Bioscience will post $0.18 EPS for the current fiscal year.
Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Harvard Bioscience in a research note on Wednesday, June 25th. They set a “buy” rating and a $9.00 price target on the stock.
Harvard Bioscience, Inc is a global developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.